Online inquiry

IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7480MR)

This product GTTS-WQ7480MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TGFB1&TGFB2&TGFB3 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000660.7; NM_001135599.4; NM_001329938.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7040; 7042; 7043
UniProt ID P01137; P61812; P10600
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7480MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10300MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ8890MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3215MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ6508MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CX-072
GTTS-WQ7535MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ3716MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ5776MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ13549MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRX-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW